共 113 条
[1]
Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood. 127 2391-2405
[2]
Orazi A(2016)Therapy-related myeloid neoplasms - what have we learned so far? World J Stem Cells 8 231-242
[3]
Hasserjian R(2013)Therapy-related myelodysplasia and acute myeloid leukemia Semin Oncol 40 666-675
[4]
Thiele J(2017)Therapy-related myeloid neoplasms: when genetics and environment collide Nat Rev Cancer 17 513-527
[5]
Borowitz MJ(2009)Therapy-related myeloid neoplasms Haematologica. 94 454-459
[6]
Le Beau MM(2016)Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: a decade of experience Cancer Biother Radiopharm 31 189-198
[7]
Zahid MF(2018)Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms Oncotarget 9 16932-16950
[8]
Parnes A(2015)Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors Eur J Nucl Med Mol Imaging 42 5-19
[9]
Savani BN(2018)Persistent hematologic dysfunction after peptide receptor radionuclide therapy with (177)Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors J Nucl Med 59 452-458
[10]
Litzow MR(2019)Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series Eur J Nucl Med Mol Imaging 46 1902-1910